This is a routine product collaboration announcement with no financial details. Monitor for future commercial adoption metrics or follow-on regulatory clearances for additional Imricor configurations in the U.S. to gauge potential revenue impact.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Aug 27 $26.92entry
- T+1 · 3mo ago −0.74%α −0.52% · $26.72
- T+5 · 3mo ago −3.23%α −3.50% · $26.05
- T+20 · 8w ago −8.80%α −8.30% · $24.55
- T+56 · todayOpen
- T+60 · in 3d Pending
Price Chart
How similar events traded
Executive Summary
Philips and Imricor announced the first commercially available Interventional MR (iMR) lab solution combining Philips' 1.5T MRI platform with Imricor's MR-compatible systems and consumables for cardiac interventions. This is a product collaboration announcement, not a financial event, and represents a strategic expansion of Philips' MRI capabilities into interventional procedures. No financial terms or revenue projections were disclosed, making this a routine product development milestone for a large-cap company like Philips.
Key Facts
- Philips and Imricor announced a new iMR lab solution combining Philips' 1.5T MRI platform with Imricor's portfolio of MR-compatible systems and consumables for cardiac interventions.
- The solution is commercially available immediately in CE-marked markets and, in some configurations, the U.S.
- The iMR lab solution is built on Philips' BlueSeal helium-free MRI technology.
- No financial terms, deal value, or revenue projections were disclosed in the press release.
Financial Impact
No financial terms disclosed; product collaboration with no stated revenue or deal value.
Risk Factors
- No financial terms disclosed, making it difficult to assess materiality.
- Regulatory clearances for additional configurations in the U.S. are pending and may face delays.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3352083 |
Track record
12 reports on PHG
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202614d ago Press Release Neutral 5/10 Entry $28.46 Now $30.14 +5.90% settles Feb 1
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $27.12 Now $30.14 +11.14% settles Jan 27
- Aug 27, 202611w ago Press Release Neutral 3/10 Viewing Entry $26.92 Now $30.14 +11.96% settles Nov 20
- Aug 24, 202612w ago Press Release Neutral 3/10 Entry $27.43 Now $30.14 +9.88% settles Nov 18
- Jul 27, 202616w ago Press Release Mixed 6/10 Entry $25.02 to $26.00 Now $30.14 +20.46% ▲ +3.92% −0.14% vs SPY
- Jun 2, 202623w ago Press Release Neutral 2/10 Entry $25.43 to $26.99 Now $30.14 +18.52% ▲ +6.13% +5.02% vs SPY
- May 15, 202626w ago Court Ruling Bullish 4/10 Entry $26.05 to $27.38 Now $30.14 +15.70% ▲ +5.11% −0.48% vs SPY
- May 6, 202627w ago Press Release Neutral 4/10 Entry $27.23 to $26.23 Now $30.14 +10.69% ▼ −3.67% −7.19% vs SPY
- Mar 23, 202634w ago Press Release Neutral 3/10 Entry $26.81 to $26.24 Now $30.14 +12.42% ▼ −2.13% −15.18% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers